Paul J Mellett Enanta Pharmaceuticals Inc (ENTA) insider trading activity

Paul J Mellett is Chief Fin. & Admin Officer of ENANTA PHARMACEUTICALS INC. Currently has a direct ownership of 91,710 shares of ENTA, which is worth approximately $550,260. The most recent transaction as insider was on Dec 06, 2024, when has been sold 2,591 shares (Common Stock) at a price of $8.06 per share, resulting in proceeds of $20,883. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 91.7K

4.37% 3M change

1.97% 12M change

Total Value Held $550,260

PAUL J MELLETT Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 06 2024	SELL Open market or private sale	$20,883 $8.06 p/Share	2,591 Reduced 2.75%	91,710 Common Stock
Dec 01 2024	SELL Payment of exercise price or tax liability	$13,717 $8.6 p/Share	1,595 Reduced 1.66%	94,301 Common Stock
Feb 12 2024	SELL Payment of exercise price or tax liability	$12,074 $12.41 p/Share	973 Reduced 1.0%	95,896 Common Stock
Feb 12 2024	BUY Grant, award, or other acquisition	-	3,320 Added 3.31%	96,869 Common Stock
Dec 05 2023	SELL Open market or private sale	$23,227 $9.63 p/Share	2,412 Reduced 2.51%	93,549 Common Stock
Dec 01 2023	SELL Payment of exercise price or tax liability	$15,136 $9.49 p/Share	1,595 Reduced 1.63%	95,961 Common Stock
Mar 15 2023	SELL Open market or private sale	$461,448 $44.2 p/Share	10,440 Reduced 9.67%	97,556 Common Stock
Mar 15 2023	BUY Exercise of conversion of derivative security	$146,160 $14.0 p/Share	10,440 Added 8.81%	107,996 Common Stock
Feb 13 2023	SELL Payment of exercise price or tax liability	$364,324 $52.77 p/Share	6,904 Reduced 6.61%	97,556 Common Stock
Feb 13 2023	BUY Grant, award, or other acquisition	-	20,997 Added 16.74%	104,460 Common Stock
Feb 09 2023	SELL Open market or private sale	$270,150 $54.03 p/Share	5,000 Reduced 5.65%	83,463 Common Stock
Jan 09 2023	BUY Exercise of conversion of derivative security	$39,874 $14.18 p/Share	2,812 Added 3.08%	88,463 Common Stock
Dec 19 2022	BUY Exercise of conversion of derivative security	$58,818 $14.18 p/Share	4,148 Added 4.62%	85,651 Common Stock
Dec 01 2022	SELL Payment of exercise price or tax liability	$46,768 $44.33 p/Share	1,055 Reduced 1.28%	81,503 Common Stock
Nov 23 2022	BUY Grant, award, or other acquisition	-	21,000 Added 20.28%	82,558 Common Stock
Jun 17 2022	BUY Exercise of conversion of derivative security	$40,960 $11.77 p/Share	3,480 Added 5.35%	61,558 Common Stock
Feb 14 2022	SELL Payment of exercise price or tax liability	$59,865 $62.49 p/Share	958 Reduced 1.62%	58,078 Common Stock
Feb 14 2022	BUY Grant, award, or other acquisition	-	3,034 Added 4.89%	59,036 Common Stock
Dec 01 2021	SELL Payment of exercise price or tax liability	$48,838 $87.68 p/Share	557 Reduced 0.98%	56,002 Common Stock
Nov 19 2021	BUY Grant, award, or other acquisition	-	6,800 Added 10.73%	56,559 Common Stock
Jan 08 2021	SELL Open market or private sale	$273,480 $45.58 p/Share	6,000 Reduced 8.85%	61,759 Common Stock
Dec 15 2020	SELL Payment of exercise price or tax liability	$32,740 $42.52 p/Share	770 Reduced 1.36%	55,759 Common Stock
Dec 15 2020	BUY Exercise of conversion of derivative security	-	2,625 Added 4.44%	56,529 Common Stock
Nov 20 2020	BUY Grant, award, or other acquisition	-	7,600 Added 12.36%	53,904 Common Stock
Nov 11 2020	BUY Exercise of conversion of derivative security	$8,839 $2.54 p/Share	3,480 Added 6.99%	46,304 Common Stock

PJM

Paul J Mellett

Chief Fin. & Admin Officer

Watertown, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ENTA shares.

Notify only if

Value

Insider Trading

Get notified when an Enanta Pharmaceuticals Inc insider buys or sells ENTA shares.

Notify only if

Operation

Value

Type

News

Receive news related to ENANTA PHARMACEUTICALS INC

Track Activities on ENTA

Account